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ABSTRACT 
 
 
Mesenchymal stem cells (MSCs) derived from bone marrow and they can 
differentiate in a variety of cell types, including osteoblasts, adipocytes, 
chondrocytes, myoblasts, hepatocytes, and neural cells. For this reason they 
provide a promising role for developing cell-based therapy for degenerative 
diseases. Understanding the mechanisms behind MSC cell fate determination 
is not easy, because the molecular processes that drive differentiation are 
complex and poorly understood. So, also if in the last years many 
improvements have been done, some problems still remain. We planned to 
investigate on differentiation of MSC and in particular we wanted to focus our 
activities towards osteoblast differentiation; at this aim, we silenced specific 
mRNAs using a mouse shRNA library present in our institute, composed of at 
least two silencing constructs for each transcript, in a 96-well-plates-based 
screening strategy.  
In the first part of this study we set up the components and the experimental 
conditions to perform the screening. After, we proceeded with the screening 
and we were able to screen a part of the library. With this methodology we 
identified genes that are possible candidates to have a role in osteoblast 
differentiation. First of all, we made a Gene Ontology classification of these 
candidates using bioinfomatic tools and we identified genes involved in different 
processes and having different functions. 
Among the candidate genes, a big part is represented by genes whose function 
is still unknown, some of which represent putative novel transcription factors 
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that we named ObI- (Osteoblast inducer-). In this study we focused our 
experiments on the first of these genes that we identified, ObI-1.  
We also considered genes whose function is known and that are involved in 
different processes but with a non described role in osteogenic differentiation. 
Among these genes we focused our attention on Serine racemase, which role 
in osteogenic differentiation was already suggested, but not largely 
demonstrated. 
For both the candidates that we treated in this study we carried out experiments 
to confirm the impairment in osteogenic differentiation as effects of their 
silencing and we made expression analyses in tissues and in our cells. 
Furthermore, as regards ObI-1 candidate, we performed a more deeply analysis 
due to characterization of his function. 
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INTRODUCTION 
 
 
1 - Adult stem cells 
An adult stem cell is an undifferentiated cell, found in a tissue or organ; this cell 
type has the ability of renew itself and differentiate to yield some or all of the major 
specialized cell types of tissues and organs. The primary role of adult stem cells in 
a living organism is to maintain and repair the tissue in which they are found. Adult 
stem cells have been identified in many organs and tissues, including brain, bone 
marrow, peripheral blood, blood vessels, skeletal muscle, skin, teeth, heart, gut, 
liver, ovarian epithelium, and testis. They are thought to reside in specific areas of 
each tissue, called "stem cell niches" (Li and Xie, 2005) . Stem cells may remain 
quiescent for long periods of time until they are activated by the need for more 
cells to maintain tissues, or by disease or tissue injury (Walker et al., 2009). 
Generally, adult stem cells are thought to be able to develop into a limited number 
of cell types related to the tissue that the stem cells originally came from. Typically, 
there is a very small number of stem cells in each tissue, and once removed from 
the body, their capacity to divide is limited, making generation of large quantities of 
stem cells difficult. Research on adult stem cells has generated a great deal of 
excitement: if differentiation of adult stem cells can be controlled in the laboratory, 
these cells may become the basis of transplantation-based therapies. 
 
 
1.2 - Adult stem cell differentiation 
Adult stem cells can differentiate through normal pathways to form the specialized 
cell types of the tissue in which they reside or they can differentiate to other tissue 
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from the cells predicted lineage (Wagers and Weissman, 2004). 
Normal differentiation pathways of adult stem cells. In a living animal, adult stem 
cells are able to divide, when needed, and can give rise to mature cell types that 
have characteristic shapes and specialized structures and functions of a particular 
tissue.  
Transdifferentiation. A number of experiments have reported that certain adult 
stem cell types can differentiate into cell types seen in organs or tissues other than 
those expected from the cells predicted lineage. This phenomenon is called 
transdifferentiation. 
Although isolated instances of transdifferentiation have been observed in some 
vertebrate species, whether this phenomenon actually occurs in humans is under 
debate by the scientific community. Instead of transdifferentiation, the observed 
instances may involve fusion of a donor cell with a recipient cell. Another 
possibility is that transplanted stem cells are secreting factors that encourage the 
recipient's own stem cells to proliferate and begin the repair process. Even when 
transdifferentiation has been detected, only a very small percentage of cells 
appears to be able to undergo the process. 
In a variation of transdifferentiation experiments, scientists have recently 
demonstrated that certain adult cell types can be "reprogrammed" into different cell 
types using a well-controlled process of genetic modification (Takahashi and 
Yamanaka, 2006). This strategy may offer a way to reprogram available cells into 
different cell types that have been lost or damaged due to diseases.  
In addition to reprogramming cells to differentiate into a specific cell type, it is now 
possible to reprogram adult somatic cells to acquire a  pluripotent state; these cells 
have been demonstrated induced pluripotent stem cells, (iPSCs) (Welstead et al., 
2008). Thus, a source of pluripotent cells specific to the donor, (thereby avoiding 
issues of histocompatibility) can be generated and used for tissue regeneration. 
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However, like for embryonic stem cells, methods by which iPSCs can be 
completely and reproducibly committed to appropriate cell lineages are still under 
investigation. 
 
 
2 - The bone marrow system 
The bone marrow is a tissue found in the hollow interior of bones. This organ is 
composed of hematopoietic and the mesenchymal lineages: the first give rise to 
the blood lcells while the second includes non-hematopoietic cells that can support 
hematopoiesis and mesenchymal stem cells and their progeny, such as 
osteocytes, chondrocytes and adipocytes (Fig. 1). 
 
2.1 - Bone marrow stromal cells 
Bone marrow stromal cells, BMSCs, are a well-characterized population of adult 
stem cells. These cells can differentiate into a variety of cells, including adipocytes, 
cartilage, bone, tendon and ligaments, muscles cells, skin cells and even nerve 
cells. 
Unlike most other human adult stem cells, BMSCs can be obtained in quantities 
that are suitable for clinical applications, making them good candidates for use in 
tissue engineering. Techniques for isolation and amplification of BMSCs have 
been established and the cells can be maintained and propagated in culture for 
long periods of time, mantaining their capacity to form all the above cell types. 
The majority of culture techniques still take a colony forming unit-fibroblast, CFU-f, 
approach: raw unpurified bone marrow or ficoll-purified bone marrow monocytes 
are plated directly into cell culture plates or flasks and BMSCs, but not red blood 
cells or haematopoetic progenitors, are adherent to tissue culture plastic within 24 
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to 48 hours (Friedenstein et al., 1966; Friedenstein et al., 1970; Owen et al., 
1988). Other flow cytometry-based methods allow the sorting of bone marrow cells 
for specific surface markers. They are tipically negative for CD34, CD45, CD14, 
CD11b, Cd19, CD79a and HLA-DR and have been shown to pe positive for Stro-1, 
CD29, CD73, CD90, CD105, CD166, CD44 and CD133 (Dominici M et al., 2006). 
Furthermore, BMSCs can be transduced, a phenomenon that could be exploited 
for the delivery of beneficial molecules to targeted locations.   
 
 
Figure 1: The Bone marrow system 
The bone marrow is the source of two distinct lineages, the haemtopoietic and the mesenchymal 
lineage. From he haematopoietic lineage derive blood cells; from the mesenchymal stem cells 
derive the supporting stromal cells, osteocytes, chondrocytes and adipocytes. Adapted from 
http://stemcells.nih.gov.  
 
 
 Animal in vivo experiments aimed at reconstitution of damaged tissues such as 
cartilage, bone, muscle, heart muscle and tendon using BMSCs cells have shown 
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great promises for clinical applications.  
 
2.1.1 - Differentiation Potential of BMSCs 
The differentiation of BMSCs is influenced by convergence of intrinsic cellular 
signals and extrinsic micro-enviromental cues from the surrounding stem-cell 
niche, but all the specific signals involved remain largely unknown (Watt et al., 
2000). 
Niche-external signals: the external signals that control stem cell fate collectively 
make up the stem cell micro-environment, or niche. A complex interplay of short- 
and long-range signals between stem cells, their differentiating daughters, and 
neighbouring cells are involved in niche maintenance. Soluble factors, cell-cell 
interaction and cell-extracellular matrix interaction seem to contribute to the self-
renewal of different type of stem cells (Watt et al., 2000; Moore et al., 2006; Wilson 
et al., 2006). The most important signals implicated in BMSC stemness 
maintenance are some cytokines such as leukaemia inhibitory factor, LIF (Jiang et 
al.,2002; Metcalf et al., 2003),  fibroblast growth factors, FGFs (Bianchi et al., 
2003; Zaragosi et al., 2006), and mammalian homologues of Drosophila wingless, 
Wnts (Boland et al., 2004; Ling et al., 2008 ). 
Niche-intrinsic signals: intrinsic regulators of self-renewal include proteins 
responsible for setting up cell division, nuclear factors controlling gene expression, 
chromosomal modification and telomere length (Watt et al., 2000). Embryonic 
stem cells (ESCs) maintain pluripotency by a transcriptional program that 
suppresses differentiation; this property is regulated by a small number of ESCs 
specific transcription factors such as Nanog, Oct-4 and Sox-2, whose expression 
is down-regulated early during embryogenesis (Boiani et al, 2005). In the last 
years several groups have shown the expression of Oct-4, Nanog and Sox-2 in the 
most undifferentiated BMSCs (Jiang et al., 2002; Beltrami et al., 2007). 
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The identification of specific signalling networks and master regulatory genes that 
regulate BMSC differentiation in specific lineages remain a challenge. Gene 
repression and induction may be main mechanism involved in the maintenance of 
the niche (Quesenberry et al., 2002). Upon stimulation, multipotent uncommitted 
BMSCs undergo asymmetric division, giving rise to two daughter cells, one being 
exact replica of the mother cell and manintaining multilineage potential, and other 
daughter cell becoming a precursor cell, with a restricted developmental program 
(Quesenberry et al., 2002). To date, the mechanism that governs the transit of 
uncommitted stem cells to partially committed precursor or progenitor cells, and 
then to fully differentiated cells is not fully understood. 
 
2.1.1.1 - Adipogenesis 
The nuclear hormone receptor peroxisome proliferation activated receptor gamma, 
PPARγ, is a critical adipogenic regulator promoting BMSC adipogenesis while 
repressing osteogenesis (Rosen et al., 2006). The bipotent co-regulator TAZ was 
recently discovered to function as a coactivator of Runx2 and as a co-repressor of 
PPARγ, thus promoting osteogenesis while blocking adipogenesis (Hong et al., 
2005). A similar role is played by Wnt signalling: the suppression of Wnt signalling 
is required for adipogenesis (Liu et al., 2004). 
 
2.1.1.2 - Chondrogenesis 
Chondrogenic differentiation of BMSCs in vitro mimics that of cartilage 
development in vivo. The transcription factor Sox-9 is considered the master gene 
of chondrogenesis and is responsible for the expression of extra cellular matrix 
(ECM) genes such as collagen types II and IX, aggrecan, biglycan, decorin and 
cartilage oligomeric matrix protein (Goldring et al., 2006). However, the specific 
signaling pathways that induce the expression of these chondrogenic genes 
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remain largely unknown. Naturally occurring human mutations and molecular 
genetic studies have identified several relevant signaling molecules, including 
various transforming growth factor β (TGF-β), bone morphogenetic protein (BMP) 
(Massague et al., 2000), growth and differentiation factor, GDF (Chen et al., 2004), 
and Wnt ligand (Hartmann et al., 2006). 
 
2.1.1.3 - Osteogenesis 
During osteogenesis, multipotent BMSCs undergo asymmetric division and 
generate osteoprecursors, which then progress to form osteoprogenitors, pre-
osteoblasts, functional osteoblasts and osteocytes. This progression from one 
differentiation stage to the following is accompanied by activation and subsequent 
inactivation of transcription factors and expression of bone related marker genes. 
 
 
3 - Osteogenic differentiation of BMSCs 
In the osteogenic differentiation of BMSCs are involved a number of growth 
factors, the relative signaling pathways that they activate and a number of cellular 
products, especially transcription factors. In this section are described some of the 
most important growth and transcription factors involved in osteogenesis (Fig. 2). 
 
3.1 - Growth factors involved in osteoblast differentiation 
 
3.1.1 - Bone Morphogenetic Proteins 
BMPs are members of the TGF-superfamily of polypeptides, which includes TGF-
s, activins, and inhibins (Wozney JM et al, 1988); they were originally identified 
because of their ability to induce endochondral bone formation. BMP proteins 
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display extensive conservation among species having seven characteristic 
cysteine knot domains (Wang EA et al., 1990). The conserved cysteine domains 
participate in the formation of an interchain disulfide bond between two monomers 
to form a dimeric precursor protein. The precursor dimers are secreted as 
propeptides, which are activated by proprotein convertases (Cui Y et al., 1998). 
 
 
Figure 2: Signalling and transcription factor regulation in osteogenic differentiation 
Wnt and BMP pathway induce osteogenic differentiation through the up-regulation of some 
osteo-specific transcription factors such as Runx2, Osterix, Dlx5 and Msx2. 
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To date, around 20 BMP family members have been identified and characterized. 
BMPs signal explicates through serine/threonine kinase receptors, composed of 
type I and II subtypes. Three type I receptors have been shown to bind BMP 
ligands, type IA and IB BMP receptors (BMPR-IA or ALK-3 and BMPR-IB or ALK-
6) and type IA activin receptor (ActR-IA or ALK-2) (Koenig et al., 1994; ten Dijke et 
al., 1994). Three type II receptors for BMPs have also been identified and they are 
type II BMP receptor (BMPR-II) and type II and IIB activin receptors (ActR-II and 
ActR-IIB) (Yamashita et al., 1995; Rosenzweig et al., 1995). These receptors are 
differentially expressed in various tissues. Type I and II BMP receptors are both 
indispensable for signal transduction. After ligand binding they form a 
heterotetrameric-activated receptor complex consisting of two pairs of a type I and 
II receptor complex (Moustakas et al., 2002). The type I BMP receptor substrates 
include a protein family, the SMAD proteins, that play a central role in relaying the 
BMP signal from the receptor to target genes in the nucleus. Smad1, 5 and 8 are 
phosphorylated by BMP receptors in a ligand-dependent manner (Hoodless et al., 
1996; Chen et al., 1997). After phosphorylation they form a complex with Smad4 
and then are translocated into the nucleus where they interact with other 
transcription factors. BMPs can activate Smad-indipendent pathway such as 
Ras/MAPK pathway (Attisano et al., 2002; Lai et al., 2002). BMP-2 activates ERK 
and p38 through Ras kinase stimulation and, as result of this activation, ATF-2 and 
Fos/Jun protein are up-regulated and interact with activating protein-1, AP-1, 
sequences in the regulation of the expression of different genes. The activation of 
p38 is essential for the expression of BMP-2, type I collagen, osteocalcin, alkaline 
phosphatase and the activation  of p38 and ERK is essential for the expression of 
fibronectin and ostepontin (Lai et al., 2002). MAPKs pathway can activate different 
pathways independently or in sinergistic way with SMAD (Attisano et al., 2002). 
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3.1.2 - BMP pathway in osteoblast differentiation 
Although BMPs are synthesized by skeletal cells, their synthesis is not limited to 
bone because they are expressed by a variety of extraskeletal tissues in which 
they play a critical role in development and cell function. BMPs increase 
commitment of cultured marrow stromal cells to osteoblast phenotype by 
increasing CBFA1 mRNA expression (Lee et al., 2002; Ito et al., 2003). BMP-4 
mRNA levels are BMP-dependent: in fact, BMPs cause an early, short-lived, 
induction of BMP-4 mRNA in osteoblasts followed by an inhibitory effect, 
suggesting autocrine regulation (Pereira et al., 2000). The transient increase in 
BMP-4 expression induced by BMPs may be required to force cell progression 
toward a differentiated state, whereas the down-regulation suggests a local control 
mechanism. BMP-2 also can be up- and down-regulated by other BMPs in 
osteoblasts, and it is of interest that BMP-2 and -4 promoters contain Runx-
2/Cbfa-1 binding sequences (Helvering et al., 2000; Ghosh-Choudhury et al., 
2001). This opens the possibility for a positive feedback loop regulating BMP-2 
and -4 expression involving Runx-2/Cbfa-1 because BMPs induce Runx-2/Cbfa-1 
expression (Banerjee et al., 2001). In long-term cultures of osteoblasts, there is an 
increase in BMP-4 mRNA expression after cell maturation, which may be 
secondary to a larger pool of cells expressing Runx-2/Cbfa-1 (Chen et al., 1997). 
 
3.1.3 - Wnt pathway in osteoblast differentiation 
Wnt proteins act on target cells by binding to Frizzleds (Fzs), sevenspan 
transmembrane receptor proteins, and LRP-5/6, single-span transmembrane co-
receptor proteins. The canonical Wnt pathway affects cellular functions by 
regulating β-catenin levels and subcellular localization (Akiyama, 2000). The 
canonical Wnt pathway is initiated by the binding of appropriate Wnt ligands to the 
Fzs and LRP-5/6 co-receptor. In absence of appropriate Wnt ligands, β-catenin is 
19 
 
phosphorylated and polyubiquitinated for the following proteasome-mediated 
degradation (Ikeda et al., 1998; Eastman et al., 1999). In presence of an 
appropriate Wnt ligand, binding of Wnt to receptor complex leads to the activation 
of the intracellular protein, Dishevelled (Dvl), that inhibits β-catenin degradation 
that accumulates and translocates to the nucleus, where in concert with members 
of the T cell factor/lymphoid enhancer factor (TCF/LEF) family, activates the 
transcription of a wide range of genes. 
The Non-canonical Wnt pathway functions in a β-catenin independent manner 
(Gordon et al., 2006). Non-canonical Wnt signals are transduced through Fz family 
receptors and coreceptors, such as ROR2 and RYK, but not LRP-5 or LRP-6 
(Katoh et al., 2007). This binding mediates the signaling through G-protein, protein 
kinase C (PKC) or calcium/calmodulin-dependent protein kinase II (CamKII) to 
induce nuclear factor of activated T cells (NF-AT) and other transcription factors 
(Wang et al., 2003; Kohn et al., 2005). Taken together, although the specificity 
between Wnt molecules and Fz receptors remains unclear, it is known that 
different Wnt ligands will preferentially activate canonical or non-canonical Wnt 
pathways (Johnson et al., 2007). 
 
3.1.4 - Wnt pathway in osteoblast differentiation 
Members of the Wnt family participate and play a central role in a variety of 
fundamental processes during embryonic development, such as limb 
skeletogenesis (Yang et al., 2003). Wnt pathway also represents a mechanism in 
mesenchymal cells proliferation and differentiation during chondrogenesis or 
osteogenesis. For example, Wnt-3a has been shown to promote proliferation and 
suppress osteogenic differentiation of adult MSCs (Boland et al., 2004), 
suggesting canonical Wnt signaling pathway functions in maintaining an 
undifferentiated, and proliferating progenitor MSC population. Wnt pathway is also 
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involved in BMPs-mediated osteogenesis (Fischer et al., 2002; Chen et al., 2007) 
and is able to induce the osteoblastic transcription factors, Cbfa-1, Dlx-5, and 
Osterix. These data strongly indicate that Wnt pathway is intimately associated 
with bone regenerative process. Two microarray gene expression studies in a rat 
closed fracture model revealed that several genes for Wnt signaling components 
and their target genes are up-regulated (Hadjiargyrou et al., 2002; Zhong et al., 
2006). These data indicate that Wnt signaling pathway is also activated during 
fracture healing. 
 
3.2 - Transcription factors involved in osteoblast differentiation 
 
3.2.1 - Runx2 
Runt-related transcription factor (Runx)-2 or corebinding factor (Cbfa)-1 plays a 
critical role in the differentiation of cells toward an osteoblastic pathway (Banerjee  
et al., 2001). Gene-targeted disruption of Runx-2/Cbfa-1 results in disorganized 
chondrocyte maturation and a complete lack of bone formation due to an arrest of 
osteoblast development (Ducy et al., 1997; Komori et al., 1997). Runx-2/Cbfa-1 
also plays a role in mature osteoblastic function, and transgenic animals 
overexpressing a dominant negative form of Runx-2/ Cbfa-1, under the control of 
the osteoblastic specific osteocalcin promoter, display decreased bone formation 
due to impaired osteoblastic function (Ducy et al., 1999). This indicates a dual role 
of Runx-2/Cbfa-1 in cells of the osteoblastic lineage, regulating osteoblastogenesis 
as well as the function of mature osteoblasts. The role of Runx-2/Cbfa-1 in later 
stages of differentiation is less clear, and its overexpression under the control of 
the type I collagen promoter results in osteopenia because of the lack of terminal 
maturation of osteoblastic cells (Liu et al., 2001).  
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3.2.2 - Osterix 
Osterix is a zinc finger transcription factor expressed by osteoblasts and required 
for endochondral and intramembranous bone formation. Osterix-null mice have 
normal cartilage development but fail to develop a mineralized skeleton 
(Nakashima et al., 2002). Osteoblast differentiation is arrested, and histological 
analysis reveals absence of trabecular bone. Osterix-null mice have reduced or 
absent expression of a variety of bone matrix proteins, including type I collagen, 
bone sialoprotein, osteonectin, osteopontin, and osteocalcin, confirming a role in 
the induction of osteoblast differentiation and function. In contrast to Runx-2/Cbfa-
1-null mice that do not form osteoblasts, osterix-null mice form cells of the 
osteoblastic lineage that express Runx-2/Cbfa-1, but the cells do not mature. This 
would indicate that osterix has effects on skeletal development that are 
independent of Runx-2/Cbfa-1 and that acts downstream of Runx-2/Cbfa-1 
(Nakashima et al., 2002). 
 
3.2.3 - Msh 
The Msh family of homeobox genes includes Msx 1, 2, and 3. Msx 3 is expressed 
in the central nervous system, whereas Msx 1 and 2 are expressed in skeletal 
tissue and modulate osteogenesis. Msx 1-null mice display cleft palate and 
craniofacial and dental developmental abnormalities, and Msx 2-null mice have 
defects in skull ossification, which are enhanced in double Msx 1/Msx 2 mutants 
(Satokata et al., 2000). Msx 2-null mice have defective chondrogenesis and 
osteogenesis due to a decreased number of osteoprogenitor cells. The skeletal 
abnormalities are associated with decreased expression of Runx-2/Cbfa-1, 
indicating that Msx 2 is necessary for osteogenesis and acts upstream of Runx-
2/Cbfa-1. However Msx2 represses transcription of osteocalcin directly by binding 
the promoter. Because osteocalcin is expressed late in osteoblast differentiation 
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and is potentially regulated by Msx2, this transcription factor may have role in both 
early and late differentiation events (Dodig et al., 1999). 
 
3.2.4 - Dlx 5  
The mammalian homolog of Drosophila distalless (Dlx) 5 is homeobox genes 
essential for craniofacial and skeletal development (Robledo et al., 2002). Dlx 5 
mRNA is expressed in osteoblasts after differentiation, concomitant with a decline 
in Msx 2 mRNA and with the appearance of osteocalcin transcripts (Ryoo et al., 
1997). BMP induces Dlx 5 expression in osteoblasts and overexpression of Dlx 5 
induces an increase of alkaline phosphatase activity, osteocalcin, and 
mineralization of the extracellular matrix (Miyama et al., 1999). Targeted gene 
inactivation of Dlx 5 results in severe skeletal abnormalities but Runx2 expression 
is unaltered (Robledo et al., 2002). 
 
 
4 - Bone tissue 
Bone, although strong, is a constantly changing tissue that has several functions. 
Bones serve as rigid structures to the body and as shields to protect delicate 
internal organs. They provide housing for the bone marrow, where the blood cells 
are formed and a point of attachment for skeletal muscles. Bones also maintain 
the body's reservoir of calcium and phosphate. 
Bones have two shapes: flat, such as the plates of the skull and the vertebrae, and 
tubular, such as the thighbones and arm bones, which are called long bones. All 
bones have essentially the same structure. The hard outer part, cortical bone, 
consists largely of proteins, such as collagen, and a substance called 
hydroxyapatite, which is composed mainly of calcium and other minerals. 
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Hydroxyapatite is largely responsible for the strength and density of bones. The 
inner part of bones, trabecular bone, is softer and less dense than the hard outer 
part. Bone marrow is the tissue that fills the spaces in the trabecular bone. Bone 
marrow contains specialized cells (including stem cells) that produce blood cells. 
Blood vessels supply blood to the bone, and nerves surround the bone. 
Bones undergo a continuous process of remodeling. In this process, old bone 
tissue is gradually replaced by new bone tissue. Every bone in the body is 
completely reformed about every 10 years. To maintain bone density and strength, 
the body requires an adequate supply of calcium, other minerals, and vitamin D.  
Bones are covered by a thin membrane called the periosteum. Injury to bone 
transmits pain because of nerves located mostly in the periosteum. Blood enters 
bones through blood vessels that enter through the periosteum. 
A characteristic of all connective tissues, including bone and cartilage, is that they 
contain a large amount of intercellular substance surrounding cells. There are four 
important types of cells associated with bone tissue: osteogenic cells, osteoblasts, 
osteocytes, and osteoclasts (Fig. 3).  
 Osteogenic cells are pre-osteoblast cells derived from mesenchyme, 
which is the precursor for all forms of connective tissue. When osteogenic 
cells undergo mitosis, the resulting daughter cells are called osteoblasts 
 Osteoblasts are fully differentiated cells that cannot reproduce. They 
are responsible for bone formation, secreting the organic substances and 
mineral salts used in ossification processes. Osteoblast possess receptors 
for hormone regulating bone growth 
 Osteocytes are osteoblasts that have become isolated in the 
intercellular substance that they have deposited around themselves. They 
are cells that have stopped laying down new bone, but play a role in 
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maintaning the cellular activities of bone tissue in their immediate area 
 Osteoclasts are formed by the fusion of monocytes in the 
endosteum. They are found on bone surfaces and function in bone 
resorption. They have receptors for various hormones that regulate their 
activity 
 
Figure 3: Bone tissue cells 
There are four main types of bone cells in bone tissue. Osteogenic cells respond to traumas, such 
as fractures, by giving rise to bone-forming cells. Osteoblasts (bone-forming cells) synthesize and 
secrete protein and matrix important for the mineralization and are found in areas of high 
metabolism within the bone. Osteocytes are mature bone cells made from osteoblasts that have 
bone tissue around themselves. These cells maintain healthy bone tissue by secreting enzymes 
and controlling the bone mineral content; they also control the calcium release from the bone tissue 
to the blood. Osteoclasts are large cells that break down bone tissue. They are very important to 
bone growth, healing, and remodeling.   
 
 
4.1 - Ossification 
There are two kinds of bone formation: intramembranous ossification and 
endochondral ossification. In both ossification processes, pre-existing connective 
tissue is replaced by bone. In intramembranous ossification, some mesenchyme 
cells are transformed into osteoblasts and start laying down bone. 
This is an ossification process that transforms membrane into bone. Additional 
bone is formed around the edge of this center until the entire membrane is 
ossified. Intramembraneous ossification is the process used to make flat bones 
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such as the mandible and flat bones of the skull. In endochondral ossification, a 
hyaline cartilage model of the bone is replaced and ossified. This is the process 
associated with fetal bone development, day-to-day bone growth, and fracture 
repair. This is the type of bone formation found in the development of long bones 
such as the femur and humerus (Fig. 4). 
 
 
5 - Bone related pathologies  
 
5.1 - Fractures 
A fracture is a partial or complete break in continuity of the bone that occurs under 
mechanical pressure. Most fractures are caused by traumatic injury, however bone 
cancer or metabolic disorders can also cause fractures by weakening the bone. 
Fractures may result in loss of function in the affected limb, guarded movements, 
pain, soft tissue swelling (edema), and deformity. 
Fractures are classed anatomically, by the extent of the injury, or by the angle of 
the fracture. 
 
5.1.1 - Fracture repair 
There are four phases in fracture repair (Fig. 5): 
Hematoma formation: when a bone breaks, the blood vessels in the bone, 
periosteum and surrounding tissues also break. This results in a mass of clotted 
blood, or hematoma, forming at fracture site 
Fibrocartilaginous callus formation: capillaries grow into hematoma and phagocytic 
cells consume the cellular debris. .Fibroblasts and osteoblasts also migrate into 
the hematoma from the periosteum and endosteum and starts to produce 
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cartilage. Some fibroblasts produce collagen fibers that link the broken bones 
together, while some osteoblasts start producing spongy bone. The entire mass of 
soft tissue produced is called fibrocartilaginous callus and serves to split the 
broken bone together. 
 
 
Figure 4: Endochondral ossification 
Endochondral ossification begins in points in the cartilage called primary ossification centers. They 
mostly appear during fetal development, through a few short bones begin their primary ossification 
after birth. They are responsible for the formation of the diaphyses of long bones, short bones and 
certain parts of irregular bones. Secondary ossification occurs after birth, and forms the epiphyses 
of long bones and the extremities of irregular and flat bones. The diaphysis and both epiphyses of 
a long bone are separated by a growing zone of cartilage.  
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Bone callus formation: osteoblasts and osteoclasts continue to migrate into the 
fibrocartilaginous callus and convert the existing callus to a bone callus made up 
of spongy bone. 
 
5.2 - Osteoporosis 
Osteoporosis refers to a set of diseases in which bone resorption overwhelms 
bone formation. Normal bone mass becomes reduced, and bones become more 
porous, weaker, and lighter. Osteoporosis usually affects the spongy bone of the 
spine, leading to compression fractures between  vertebrae. The head of the 
femur also often fractures in people with osteoporosis. 
Estrogen acts to inhibit osteoclasts activity, and when estrogen levels decrease, 
osteoclasts activity increases to erode the bone matrix. Other factors contributing 
to osteoporosis can include: an inactive lifestyle, a diet low in calcium and protein, 
or as consequences of other diseases such as hyperthyroidism. 
 
5.3 - Osteoarthritis 
Osteoarthritis, or degenerative joint disease, is the most common form of chronic 
arthritis. In this disease, the articular cartilade degenerates and bone grows into 
the joint space. As the joint space decreases, movement becomes more difficult 
and painful. Osteoarthritis occurs as a consequence of aging and “wear and tear” 
on a joint over the years 
 
 
6 - High troughput screening 
High-Throughput Screening (HTS) allow to quickly conduct large numbers of 
biochemical, genetic or pharmalogical tests. Through these processes it is 
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possible identify active compounds, antibodies or genes which modulate a 
particular biomolecular pathway. The results of these experiments provide starting 
points for understanding the interaction or role of a particular biochemical process 
in biology and for drug design. Essentially, HTS uses automation to perform 
screenings of a particular assay against a library of candidate compounds.  
An assay is a test for a specific activity such as inhibition or stimulation of a 
biochemical or biological mechanism. The key labwares for HTS are microplates 
wich generally have 384, 1536 or 3456 wells; these are all multiple of 96 well 
plates. Each well contains a specific compound to test. After the test, it is 
necessary manual or automated analysis of results. 
Automation is an important element in HTS utility. Typically, an integrated robot 
system transports assay microplates from station to station for sample and reagent 
addition, mixing, incubation, and finally read out or detection. An HTS system can 
usually prepare, incubate and analyze many plates simultaneously; currently HTS 
robots can test up to 100,000 compounds per day.  
It is occasionaly HTS cannot be completely automated: in this case an operator 
need to perform the assay for the candidates compounds. The difference between 
automated and non automated system depends upon the type and the complexity 
of the screening. 
 
6.1 - High-throughput screening with RNA interference-based 
approach 
A classic example of activity used by HTS is gene silencing with RNA interference 
technique. In fact, many libraries of RNA interference molecules validated for their 
sequence and acting versus most of the genome sequence of human and mice 
are available. 
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Figure 5: Physiology and process of facture healing 
After the bone fracture, there are four major phases of bone tissue healing: formation of 
fracture hematoma, fibrocartilaginous callus formation, bony callus formation and bone 
remodelling. 
 
 
Target sequences are selected on the basis of thermodynamic criteria in order to 
reach a strong silencing efficiency. 
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Loss of function phenotypes are often the key to understand the function of genes 
involved in biological processes: in this case RNA interference technique is used 
to identify the role of a gene towards its silencing. 
Recently, a lot of research groups focused their activity on this type of approach: 
many scientific articles refer about the use of high-throughput screening to 
investigate about a specific biological process. There are many studies about the 
investigation of genes functioning in a specific cellular processes in mammalian 
cells: One example is the research of several genes involved in mammalian cell 
cycle using a strategy based on RNA-interference (Kittler et al., 2008). 
Furthermore, HTS had been applied also in other system such as Drosophila 
Melanogaster to find genes involved in development (Perrimon and Mathey-
Prevot, 2007). 
 
 
7 - RNA-Interference 
 
7.1 - Biological functions and effectors 
RNA interference (iRNA) is a form of post-transcriptional gene silencing mediated 
by a little double-strand molecule of RNA (dsRNA, double strand RNA) capable of 
block messenger RNA target molecules that will not be able to be translated. 
This is a natural process preserved during the evolution and it is involved in 
several mechanisms: 
 Protection against genome instability 
 Defence against viral attacks 
 Gene expression regulation 
 Developmental regulation 
31 
 
RNA interference can be activated by a double strand of RNA brought into the cell 
(siRNA, small interfering RNA) that leads to the degradation of mRNA target. RNA 
interference can be also activated by small non codifying transcripts synthesized 
within the cell (miRNAs, micro RNA): in this case not always the mRNA target is 
degradated through cleavage. 
Main effectors of RNA interference process are: 
miRNA: miRNA are short single-strand molecules of RNA of about 20-22 
nucleotides with a 5’P Cap and 2 nucleotides 3’ protruding. Their biogenesis starts 
in the nucleus: their corresponding genes are located in the intergenic regions and 
in transcriptional units both in the sense and anti-sense orientation (Lagos-
Quintana et al., 2001; Lau et al., 2001; Maurelatos et al. 2002).  
miRNA are first synthesized as primary miRNA (pri-miRNA) containing the 5’ Cap 
and a polyadenilation sequence at 3’; then they are processed by Drosha RNA 
polymerase III that generates molecules of 70-80 nucleotides with a stem and loop 
structure, precursor miRNA (pre-miRNA). Pre-miRNA are translocated from 
nucleus to cytoplasm by a complex of receptors on the nuclear membrane, such 
as exportin5 (Lund et al., 2004; Bohnsack et al., 2004). 
Pre-miRNA are processed in miRNA by Dicer, a ribonucleasic enzyme of the RNA 
polymerase III family with two catalytic domains and one dsRNA-binding domain. 
Each miRNA binds the enzymatic complex RISC (RNA-interference silencing 
complex), forming a RNA-protein complex named miRISC (Fig. 6). 
Small RNA molecules are then separated: the sense strand is degradated while 
the antisense strand is drove toward the mRNA target by a RISC complex subunit, 
Argonauta 2 (Ago2) (Liu et al., 2004). If miRNA and mRNA target strands are 
highly complementary, RNA is cleaved; otherwise they are partly mismatched, 
RISC complex linked to mRNA does not allow the normal ribosomes translation. In 
both cases no protein is made. 
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siRNA: siRNA are short molecules of double-strand RNA of 21-23 nucleotides with 
two phosphate groups at 5’ and 2 nucleotides 3’ protruding generated bt Dicer. 
They can be introduced  into the cells by both transfection and infection.  
The antisense strand binds the RISC complex forming the RNA-protein complex 
siRISC which recognize the mRNA target and cleave it (Fig. 7). 
shRNA: short hairpin RNA (shRNA) are small RNAs with a stem and loop 
structure: they mimic the pre-miRNA structure and so follow their same 
processing. shRNA are expressed by plasmids or viral vectors and for this reason 
they present the advantage to perform a stable silencing of their mRNA targets. 
 
7.2 - Off-target effects 
Off-target effects are defined as the consequences of not desired interactions 
between RNA interference molecules and cellular components or no target mRNA. 
 
7.2.1 - Sequence-independent effects  
Among the sequence-independent effects there are transfection conditions and 
inhibition of the endogenous activity of miRNA. miRNA endogenous activity 
inhibition may be provoked by RNA-interference machinery saturation: an example 
is the saturation of the exportin5 (Yi et a., 2005). 
 
7.2.2 - Sequence-depended effects 
Among the sequence-depended effects there are immune response stimulation 
and interaction with no mRNA targets. The immune response can be provoked by 
type I interferons when siRNA are longer than 30 base pair. Another mechanism is 
the recognition of single- or double-strand RNA molecules by Toll-like receptors 
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(TLRs) which leads the inflammatory response towards NFkB, IRF and ATF2 
transcription factors in the nucleus.  
 
 
Figure 6: Functional model of the miRISC complex in human 
miRNA are transcripted by RNA polymerase II in primary miRNA (pri-miRNA) of 60-100 nucleotids. 
Pri-miRNAs are cleaved by Drosha to form precursor miRNA (pre-miRNA) of 60-70 nucleotids 
containing 2 nucleotids 3’ protruding. Pre-miRNAs are traslocated into cytplasm by exportin5-
RanGTP complex and by other adapter proteins. In cytoplasm, pre-miRNA are processed in short 
molecules (~22- nt), miRNAs, by Dicer. After, miRNA bind protein complex RISC containing several 
known proteins such as AGO2, AGO1, Dicer, TRBP e RCK and unknown proteins. RISC complex 
drive antisense strand towards mRNA target. 
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It is possible to reduce the interferon-mediated response avoiding the presence of 
some nucleotids motifs, such as GU traits, in the small RNA sequences (Judge et 
al., 2005). The main reason of sequence-depended off target effects are however 
the interaction between RNA-interference effectors and no target mRNA. To avoid 
this problem is important verify that a RNA-interference molecule has the minimal 
omology with other mRNA sequences other than its mRNA target.  
Two solution for this problem are redundancy and phenotype rescue experiments 
(Fig. 8). In the redundancy experiments are used different effectors having the 
same mRNA target: in this way probability that two distinct RNA molecules share 
the same off-target effects. In the phenotype rescue experiments it is used a 
functional version of the target gene resistant to RNA-interference effector 
(Echeverri et al., 2006). 
 
 
8 - Zinc-finger transcription factors containing the Krȕppel-
associated box family 
The largest family of zinc-finger transcription factors comprises those containing 
the Krȕppel-associated box (KRAB-containing proteins): they were first discovered 
almost 30 years ago (Bellefroid et al. 1991) and represent the largest single family 
of transcriptional regulators in mammals. Many genes encoding KRAB-containing 
proteins are arranged in clusters, but other occurs individually across the genome. 
Their structure consist in different domains with a range that can change in the 
different proteins (Urrutia, 2003) (Fig. 9). The main domains are: KRAB domain 
located near the N-terminus of the protein which act as a strong transcriptional 
repressor (Witzgall et al., 1994), and various zinc-finger domains at C-terminus 
which bind DNA (Looman et al., 2002). 
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Figure 7: Functional model of the siRISC complex in human 
Long double strand RNA or hairpin RNA are cleaved by Dicer into short interfering RNA 
molecules of 21-nucleotids (siRNAs) with 2 nucleotids 3’ protruding and a phosphate group 
at 5’. Alternatively, siRNAs can be introduced into the cells where are phosporilated at 5’ by 
cellular kinases. These small RNA assembled into RISC complex that contains AGO2, Dicer 
and other cellular factors. RISC find mRNA target which is cleaved with the possible recycle 
of the RISC complex for several cleavage events. 
 
 
The most remarkable feature of the KRAB-containing proteins is that they are 
present only in tetrapod vertebrate genomes (Urrutia, 2003). The KRAB domain is 
present in the sequences of zinc-finger proteins in the human, mouse, rat, chicken 
and frog genomes while is absent in fish, Drosophila, plants, yeast and other fungi: 
this distribution suggest that the presence of KRAB domain is relatively recent in 
the evolution. The functions known for the members of this protein family include 
transcriptional repression of RNA polymerase I, II and III promoters and binding 
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and splicing of RNA; however, functions of most of the proteins of this family have 
not been well studied. 
An example of study on one of these proteins was the characterization of a novel 
zinc-finger transcription factor containing a KRAB domain involved in bone 
development (Jheon et al., 2001). This study demonstrated the capacity of this 
factor to modulate Runx2 activity and osteogenic differentiation. 
 
 
Figure 8: Experimental controls to minimize off-targets effects in i-RNA experiments 
In redundancy experiment two RNA intreference molecules acting against two different 
regions of the same target are used. In phenotype rescue experiment a resistant version of 
the mRNA target is used.  
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9 - Serine racemase 
Serine racemase (Srr) is an enzyme that converts L-serine (L-ser) in D-serine (D-
ser) (Fig. 10). It was first found in astrocytes but recently has been detected in 
many types of neurons (Miya et al., 2008). Out of 20 amino acids in mammalian 
cells, only serine and aspartate appear in D-configuration as well as L-
configuration in significant amount: this indicates the relevance of the D-
configuration of these two amino acids and underlines their importance especially 
in the brain where they are mainly localized. D-serine is able to acts on the co-
agonist site on N-methyl-D-aspartate (NMDA) receptors increasing their activity 
(Yang and Svensson, 2008); it is as potent as glycine as coagonist and its 
distribution is analogous to NMDA receptors in the brain (Ying-Luan et al., 2007).  
 
9.1 - Glutamate receptors 
NMDA receptors have glutamate as their mayor excitatory substance in 
mammalians. Among glutamate receptors a particular class is represented by 
metabotropic (mGlu) that are G-protein coupled receptors (GPCRs): they have 
been subdivided in three groups, based on sequence similarity, pharmacology and 
intracellular signalling mechanisms. mGlu receptors group I are coupled to 
Phospholipase C (PLC) and intracellular calcium signalling, while group II and 
group III receptors are negatively coupled to adenylyl cyclase (AC). Another class 
of glutamate receptors consist in ionotropic: they are ligand gated ion channels 
that after binding glutamate, are able to exchange ions, such as Na+ and Ca2+, 
through passage into a channel in the centre of the receptor complex. This flow of 
ions results in depolarization of the plasma membrane and generation of an 
electrical signal. These receptors are multimeric assemblies of four or five 
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subunits, and are subdivided into three groups (AMPA, NMDA and Kainate 
receptors) based on their pharmacological and structural similarities.  
 
 
Figure 9: Primary structures of typical KRAB-containing zinc-finger proteins 
Different proteins of this family contain different range of functional domains. The number of zinc 
fingers vary form 4 to over 34 (for semplicity here are shown only 8 for each structure). The KRAB 
domain consist of the A and B boxes. Some members of the family have a leucine-rich SCAN 
domain that allows homo- and hetero-dimerization with other SCAN-containing zinc-finger proteins.  
 
 
 
Figure 10: D-Serine biosynthesis by Serine racemase 
Serine racemase gene converts D-serine from L-serine. 
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In particular, NMDA receptors are composed of assemblies of NR1 subunits and 
NR2 subunits, which can be encoded by four separate gene products (NR2A-
D). Expression of both subunits is required to form functional channels. The 
glutamate binding domain is formed at the junction of NR1 and NR2 subunits. In 
addition to glutamate, NMDA receptors require a co-agonist, glycine, to allow 
receptor function. Alternatively, as we mentioned above, D-serine can bind the co-
agonist site which is present on the NR1 subunit.  
 
9.2 - Glutammate signaling in bone 
Srr and D-ser are present both in peripheral tissues and in the central nervous 
system (CNS): some authors demonstrated their presence in condrocytes 
(Takarada et al. 2008) and their function in the regulation of chondrogenic 
differentiation in cartilage (Takarada et al., 2009). 
Since localizations of D-ser and its biosynthetic enzyme Srr approximate the 
distribution of NMDA receptors in brain, localization of NMDA receptor subunits in 
peripheral tissues may indicate the presence of Srr and D-ser in these tissues.  
There are many evidences that support the idea that, not only NMDA receptors, 
but also other glutamate recptors and several components of the glutamate 
signaling machnery are present in bone. 
Expression of the primary subunit of the NMDA recpetor, NMDAR1, has been 
demonstrated in osteoblast, osteocytes and osteoclasts in vitro and in vivo 
(Kalartiti et al., 2004). Furthermore, expression of different NMDAR2 subunit has 
been demonstrated in osteoclasts (Itzstein et al., 2001) and osteoblasts (Hinoi et 
al. 2002). The first evidence of the existence of a glutamatergic signaling in bone 
has been provided by the identification of the GLAST glutamate transporter in 
osteocytes (Mason et al., 1997). Several studies confirmed the presence of other 
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glutamate transporters in osteoblasts (Takarada et al., 2004). Finally, other studies 
demonstrated the presence in osteoblasts of components of the exocytotic 
machinery required to release glutamate, such as v-SNARE VAMP, t-SNAREs 
SNAP-25 and syntaxin (Bhangu et al., 2001). 
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MATERIALS AND METHODS 
 
 
10 - MATERIALS  
 
10.1 - Mouse shRNA library 
shRNA library consist in 64,000 bacterial stocks containing plasmid DNA 
expressing  shRNA constructs that cover the entire mouse transcriptome. Bacterial 
stock are stored in single wells in 96 well plates in glycerol stock at -80°C (Fig 11). 
 
 
Figure 11: Images of a mouse shRNA library plate 
Bacterial stock of the shRNA library are stored in single wells in 96 well plate (left side). Library 
plates have an ID number and a bar-code to identify the specific plates for each shRNA construct 
(right side). 
 
 
10.1.1 - Bacterial cells 
PirPlus (Pir-1)-competent bacteria (Open Biosystems). It’s a Escherichia Coli stock 
expressing the pir1 gene. 
 
10.1.2 - Plasmid DNA 
42 
 
pSM2 (pShag Magic Version 2.0; Open Biosystems) retroviral vector. This plasmid 
contains the following features: 1) Murine Stem Cell Virus (MSCV) backbone with 
Retroviral Signaling Sequences; 2) U6 promoter; 3) RK6γ conditional origin of 
replication. Requires the expression of pir1 gene within the bacterial host to 
propagate; 4) Kanamycine and Chloramphenicol  resistance as bacterial selection 
markers; 5) Puromycine resistance for selection after transfection in mammalian 
cells . 6) Sequence that express the shRNA construct (only sequence difference 
between all the plasmids (Fig 12).  
 
  
Figure 12: pShag Magic Version 2.0 features 
Structure of the DNA plasmids contained within bacterial stocks of the mouse shRNA library. Each 
plasmid contain a DNA segment for the expression of a specific DNA construct. Furthermore, 
plasmids contain several common features. 
 
 
10.2 - Cell cultures 
 
10.2.1 - Culture of cell lines 
W20-17 cells were obtained from ATCC (American Type Culture Collection). Cells 
were cultured in Dulbecco’s Modified Eagle’s Medium, High Glucose (D-MEM) 
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(Euro Clone) supplemented with 10% selected Fetal Bovine Serum (FBS) 
(HyClone) and 2mM L-Glutammine (Gibco, Invitrogen). 
 
10.2.2 - Culture of murine bone marrow stromal cells (mBMSC) 
mBMSC were obtained by isolation from mouse tibias in our laboratory (Esposito 
et al., 2009). Cells were cultured in alpha minimum essential medium (α-MEM) 
(Cambrex Bio Science) supplemented with 10% selected Fetal Bovine Serum 
(FBS) (HyClone) and 2mM L-Glutammine (Gibco, Invitrogen). 
 
10.3 - Differentiation media 
 
10.3.1 - Osteogenic medium 
D-MEM supplemented with 10% selected FBS, 2mM L-Glutammine, 0.05 mM 
ascorbic acid 2-phosphate (Sigma Aldrich), 10 mM β-glicerolphosphate (Sigma 
Aldrich), 5 x 10-3 M dexametasone (Sigma Aldrich). 
 
10.3.2 - Adipogenic medium 
D-MEM supplemented with 10% selected FBS, 2mM L-Glutammine, 5µg/mL 
insulin (Sigma Aldrich), 0,5 µM isobutylmethylxanthine (IBMX) (Sigma Aldrich), 50 
µM indometacin (Sigma Aldrich). 
 
10.4 - Solutions 
 
10.4.1 - Trypsin/EDTA 
0.2 % Trypsin (Invitrogen), 1% chicken serum (Euro Clone), 10 mM EDTA (pH=8). 
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10.4.2 - Formalin 10% 
Cells fixing solution. 10% Formaldehyde (Sigma Aldrich), 90% Water. 
 
10.4.3 - Alizarin Red S 
2%  Solution (2 g Alizarin Red S powder per 100 mL water). pH = 4.1-4.3. 
 
10.4.4 - Solutions for ALP staining 
Fixing solution: 
Neutral Formalin Buffer (NFB) 10% (+4°C). 
Staining solution: 
a) Naphtol AS MX-PO4 powder (0.005 g) in DMF (N,N-Dimethylformamide) 
(200 µL). 
b) Tris-HCl (MW = 157.6) 0.2 M, pH 8.3 (25 mL) + distilled water (25 mL). 
c) Red Violet LB salt (0.03 g) 
Note: Prepare (a) and (b) separately; add (a) + (b); add (c).  
 
10.4.5 - Oil Red 
0.5% solution (0.5 g Oil red-O per 100 mL water). 
 
10.4.6 - Guanidine HCl 
Used for Alizarin Red S staining quantitation; it was prepared at 4M.  
 
10.6 – Reagents 
• LipofectamineTM 2000 - Transfection reagent - (Invitrogen) 
• Puromycin (Sigma Aldrich). Prepared stock: 5 mg/mL. 
• Trireagent  - RNA extraction - (Sigma Aldrich). 
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• RT Buffer - Composition: 500 mM Tris-HCl (pH 8.3); 750 mM KCl; 30 
mM MgCl2; 100mM DTT.  
 
 
11 - METODS 
 
11.1 - Transfection with LipofectamineTM 2000 
Transfection with LipofectamineTM 2000 (Invitrogen) was performed following the 
procedure’s guidelines. Initially, cells were plated in the plastic support and 
allowed to growth overnight to reach the confluence of 70%-80% optimal for the 
transfection. The day after, cells were transfected with different DNA: DNA and 
Lipofectamine 2000 were separately diluted in D-MEM without serum and 
incubated for 5 minutes at room temperature (the amount of the dilution medium 
and of DNA and lipofectamine depends upon the plastic support used). After the 5 
minutes incubation the diluted Lipofectamine and diluted DNA were combined, 
mixed gently and incubated for 20 minutes at room temperature. Finally the 
reagent/DNA mixture was added to the plated cells after the change of the 
medium in which they were. After 6 hours, medium with the mixture was  removed 
and replaced with standard medium. 
In the table below are reported volumes of medium and quantities of DNA and 
reagent used in our experiment in 96 and 6 well plates (Tab. 1). 
 
11.2 - Puromycin selection 
Cells transfected with shRNA plasmids of the library were cultured for 3 days in 
medium supplemented with puromycin in order to enrich cell population that 
incorporated the plasmid DNA. Puromycin amount was established on the basis of 
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puromycin kill-curve experiments on cells for 3 days: for W20-17 the concentration 
of puromyicin used is 2.0-2.5 µg/mL. 
 
 
 
CULTURE 
VESSEL 
 
SURFACE AREA 
PER WELL 
 
VOLUME OF 
PLATING 
MEDIUM 
 
VOLUME OF 
DILUITION 
MEDIUM 
 
DNA 
 
LIPOFECTAMINE
TM
 
2000 
 
96 well 
 
0,3 cm2 
 
100 µL 
 
2 x 25 µL 
 
0,2 µg 
 
0,5 µL 
 
6 well 
 
10 cm2 
 
2 mL 
 
2 x 250 µL 
 
4,0 µg 
 
10 µL 
 
Table 1: Quantity of components for DNA transfection in 96 and 6 well plates 
Note: For DNA transfection in 96 well plates during the screening a gene reporter plasmid was co-
transfected at concentration of 70-100 ng per well in order to evaluate the efficiency of the 
transfection after 24-48 hours.  
 
 
11.3 - Differentiation assay 
 
11.3.1 - Osteogenic differentiation 
Cells are cultured for 21 days with osteogenic medium (section 10.3.1) at 37°C in 
humidified atmosphere at 5% CO2. Osteogenic medium is replaced every 3-4 
days. 
 
11.3.2 - Adipogenic differentiation 
Cells are cultured for 14 days with adipogenic medium (section 10.3.2) at 37°C in 
humidified atmosphere at 5% CO2. Adipogenic medium is replaced every 3-4 
days. 
 
47 
 
11.4 - Staining assay  
 
11.4.1 -  Alizarin Red staining  
Cells were washed with PBS and fixed in 10% formaldheyde for 1h; after rinsing 
with distilled water they were incubated with Alizarin Red S 2% solution (section 
10.4.3) with gentle agitation for 10 min. Excess staining was removed using PBS. 
 
11.4.2 - ALP staining 
Cells were washed with cold PBS and fixed with 10% cold NFB (section 10.4.4) for 
15 min. Cell were incubated with the staining solution (section 10.4.4) for 15 min 
and then were washed 3-4 times using distilled water.  
 
11.4.3 - Oil Red staining 
Cells were washed with PBS and fixed in 10% formaldehyde for 15 min; after 
rinsing with distilled water, they were incubated with Oil Red-O working solution 
(section 10.4.5) for 10 min. Excess staining was removed using PBS and cells 
were then counter-stained hematoxylin (Bio-Optica) for 3 min and washed with 
distilled water.  
 
11.5 – Staining Quantitation assay 
 
11.5.1 -  Alizarin Red staining quantitation  
Alizarin Red S solution bound to the calcium deposits was extracted using over-
night incubation with Guanidine HCl 4M (10.4.6) at room temperature. Absorbance 
at 490 nm of the resulting supernatant was used for quantitative calcium 
determination. 
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11.5.2 - Oil Red staining quantitation  
The lipid bound dye was extracted using isopropanol incubation for 15 min at room 
temperature. Quantitative assessment was obtained by measuring adsorbance of 
the extracted dye at  550 nm. 
 
11.6 - RNA extraction. 
TriReagent (Sigma Aldrich) was used in order to extract RNA from the cells. 1 mL 
of TriReagent was added to the cells (1 mL per each well of a six well plate in our 
experiments) after aspirating culture medium and washing with PBS. After addition 
of the reagent the cell lysate was passed several times through pipette to form an 
homogenous lysate. After homogenization, the homogenate was centrifuged at 
12,000 g for 10 minutes at 4°C. Following the centrifuge the clean supernatant 
was transferred to a fresh tube and left for 5 minutes at room temperature. After, 
0.2 ml of chloroform was added per 1 ml of TriReagent used initially. The sample 
was shook vigorously for 15 seconds and allowed to stand for 2-15 minutes at 
room temperature, resulting mixture was centrifuged at 12,000 g for 15 minutes at 
4°C. 
After centrifugation the upper aqueous phase containing RNA was transferred in a 
fresh tube, mixed with 1/10 of isopropanol, left for 5 minutes at room temperature 
and centrifuged at 12,000 g for 10 minutes. Subsequently, the supernatant was 
transferred to a fresh tube and the RNA was precipitated by adding 0.5 ml of 
isopropanol per 1 ml of TriReagent used in sample preparation. The sample was 
allowed to stand for 5-10 minutes at room temperature and then it was centrifuged 
again at 12,000 g for 10 minutes at 4°C. After this centrifugation the supernatant 
was removed and the RNA pellet washed by adding 1 ml of 75% ethanol per 1 ml 
of TriReagent used initially; the sample was centrifuged at 7,500 g for 5 minutes at 
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4°C. Finally, the supernatant was removed, the RNA pellet dried for 5-10 minutes 
by air-drying and risuspended in an appropriate volume of water. 
 
11.7 - RT PCR 
2 µg of RNA extracted was added to random nanomers, dNTP mix and water (until 
16 µL of final volume). Mix was incubated at 70° for 10 min and then in ice for 1 
min. After that, were added Reverse transcriptase buffer (1X) RNAsi inhibitor and 
M-MuLV Reverse Transcriptase enzyme (New England BioLabs) (final volume: 20 
µL). Program for reaction was: 42° for 1 h and 90° for 10 min. 
 
11.8 - Real-Time PCR  
Real-Time PCR was performed with LightCycler machine using Sybr Green as 
probe. PCR program for each cycle as: 50° for 2 min, 95° for 10 min, 95° for 15 
sec, 60° for 1 min, 95° for 15 sec, 60° dor 15 sec. Control is represented by 
GAPDH determination.  
 
 11.9 - Western Blot  
Cell lysates were obtained by treatment with 1% NP40 lysis buffer and 
phosphatase inhibitor. Antibodies uses were: Anti-Flag (1:500), Anti-GAPDH 
(1:1000) and secondary HRP-conjugated antibody (1:3000). 
 
11.10 – Immunofluorescence 
Cells were fixed in 4% paraformaldheyde and permeabilized with 0.2% TX-100, 
10% normal fetal bovine serum/1% bovine serum albumin in PBS for 30 min at 
room temperature. The samples were incubated with primary murine antibody anti-
Flag (1:250) and then with an anti-mouse immunoglobulin G conjugated with Alexa 
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Fluor 488 (Moleculare Probes, Eugene). Images were captured using an inverted 
microscope (DMI4000, Leica Microsystem). 
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RESULTS 
 
 
12 - Components and experimental conditions set up 
 
12.1 - Mouse shRNA library amplification 
Bacterial stock containing shRNA plasmids have been inoculated to amplify the 
mouse shRNA library. The entire procedure of amplification has been 
automated using Biomek FX robot from Beckman (Fig. 13). Bacterial stock were 
stored in 96 well plates, and our plasmid preparations were performed in the 
same support. In this way we have been able to directly transfect all the 
plasmids in W20-17 cells seeded in 96-well plate. 
To date 15,000 construct have been amplified, corresponding to 150 plates of 
the library. All the plates were catalogued in order to know the exact plate and 
well position for each construct.  
 
12.2 - In-vitro osteogenic differentiation  
In order to differentiate W20-17 cells into osteoblasts, we treated them for 21 
days with osteogenic medium or D.A.G. medium (Dexametasone, Ascorbic 
Acid-2P and β-Glicerophosphate). Treatment of mesenchymal precursors with 
this medium allows to obtain a good differentiation since these reagents act as 
osteogenic differentiation inducers. 
In order to evaluate completion of osteogenic differentiation we performed an 
Alizarin Red S staining: cells differentiated into osteoblasts form calcium 
deposits which are stained in red and are well visible at microscope analysis. 
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We also included in our experiment cells treated with normal medium as 
negative control (Fig. 14). 
 
 
Figure 13: Biomeck FX Robot from Beckman 
Biomek FX Robot used to perform automated mini-prep procedure of the bacterial stock of the 
library. 
 
 
We also quantify Alizarin Red S staining using Guanidine-HCl 4M extraction 
and absorbance reading at 490nm. 
In order to further analyze the osteogenic differentiation process in our cells, we 
performed a time course with staining and quantitation of  Alizarin Red 
adsorbance cells at different time points from day 0 until day 21. We choose 
day 5, 7, 9, 12, 14, 16, 18 and 21 as different time points and we grew cells in 
osteogenic and normal medium. For the cells grown in osteogenic medium, 
Alizarin Red S staining positivity is evident starting from day 12 with a gradual 
increase until day 21. On the contrary, cells grown in normal medium do not 
show positivity to Alizarin Red S staining for any of the time points considered 
(Fig. 15A). Microscope analysis of stained cells was confirmed by quantitation 
of staining: in fact, there is an increase of absorbance at 490 nm in the wells 
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containing cells treated with osteogenic medium, while the absorbance remains 
constant in the wells containing cells treated with normal medium (Fig. 15B). 
 
 
 
 
 
 
 
 
Figure 14: Osteogenic differentiation of W20-17 cell line 
Alizarin Red S staining of W20-17 cells cultured in either the presence or absence of osteogenic 
medium. Cells not cultured with osteogenic medium were grown with normal medium.  
 
 
12.3 - W20-17 cell line characterization  
In order to characterize W20-17 cells differentiation into osteoblasts we 
evaluated the expression of several osteoegenic marker genes along the entire 
process; this analysis was necessary to demonstrate the effective changes at 
molecular levels during differentiation. At this purpose, we evaluated the 
expression of RunX2 and Osterix, as early markers, and Osteocalcin and 
Osteopontin, as late markers, at different time points: T0, T4, T14 and T21. 
RunX2 expression has a bimodal curve: it increases from day 0 to day 4, then it 
decreases at day 14 to increase again at the last time point (Fig. 16A). On the 
other hand, Osteopontin levels increase steadiliy from day 0 to day 21 (Fig. 
16B). Osterix and Osteocalcin present an expression pattern similar to 
Osteopontin, with a very high pick at day 21 (Fig. 16C and 16D). 
 
Undifferentiated cells Differentiated cells 
medium 
54 
 
12.4 - Experimental approach validation 
Prior to the the screening we verified our experimental approach and tested the 
functionality of shRNA constructs of the library in the inhibition of the 
differentiation process. We prepared a 96-well plate with several plasmids 
expressing shRNA constructs against genes previously shown to be involved in 
the osteogenic differentiation process. We chose about 40 genes with 64 
corresponding constructs. Among these genes we included transcription 
factors, such as Runx2 and Osterix, growth factors, such as BMPs and FGFs, 
cellular regulators, such as SMAD protein and also differentiation markers such 
as osteocalcin and genes codifying for matrix proteins such as collagen. 
We transfected W20-17 cells with the 64 constructs in a 96-well plate and 
proceeded with puromycin enrichment for three days in order to obtain a larger 
number of cells containing the library plasmids.  
After puromycin treatment we continued with osteogenic differentiation for 21 
days and, finally, we performed Alizarin Red S staining and its quantitation with 
Guanidine HCl 4M (Fig. 17).  
In this experiment we chose several controls: positive and negative controls of 
differentiation, respectively represented by untransfected cells grown in 
osteogenic and normal medium, and a scrambled control for the RNA-
interference technique, achieved using a library construct codifying for an 
shRNA that does not interfere with any known gene, shRNA Non Silencing 
(shRNA-NS). For this experiment we also chose several controls to use during 
the screening, obtained using shRNA constructs that interfere with genes 
whose role in osteogenic differentiation is well demonstrated. Following Alizarin 
Red S staining after 21 days of osteogenic differentiation, results were variable:  
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Figure 15:  Osteogenic differentiation time course of W20-17 cell line 
Alizarin Red S staining of W20-17 cells cultured in normal and osteogenic medium at days 5, 7, 
9, 12, 14, 16, 18 and 21 (A). Calcium deposition quantitation using Guanidine HCl 4M and 
adsorbance reading at 490 nm (B). 
 
 
 
A 
B 
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Figure 16: Expression analyses of osteogenic differentiation markers during osteogenic 
differentiation of W20-17 cells. 
Expression profiles of Runx2 (A), Osteopontin (B), Osterix (C) and Osteocalcin (D) at days 0, 4, 
14 and 21 of differentiation of W20-17 cells  
 
 
for some genes we did not obtain any osteogenic differentiation impairment, 
while for other genes we obtained different levels of silencing, in some cases 
similar to the negative control of differentiation. 
Cells transfected with the shRNA-NS showed staining result similar to those 
obtained for the positive control of differentiation. Finally, for constructs 
interfering with genes with a demonstrated role in osteogenic differentiation we 
obtained different levels of Alizarin Red S staining impairment. We reported 
staining and relative quantitation for the negative and positive control of 
osteogenic differentiation; furthermore, we reported the staining for cells 
transfected with the shRNA-NS and cells transfected with shRNA interfering 
with Smad5 and Bmp1 genes as best examples of genes involved in the 
osteogenic differentiation which silencing produced effects in our experiment 
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(Fig. 18A and 18B). Library constructs that interfere with these two genes were 
chosen as control for the screening. 
 
 
Figure 17: Experimental approach to perform the screening 
Cells are plated in 96 well-plates and transfected after one day with shRNA plasmids. Co-
transfection with a plasmid for the expression of a reporter gene is performed to supervise 
transfection efficiency. Then, cells are cultured for 2-3 days in presence of puromycin in order to 
enrich cellular population that incorporated the shRNA plasmids. Finally, cells are cultured in 
osteogenic medium to differentiate into osteoblasts.  
 
 
13 - Screening 
 
13.1 - Transfection of shRNA mouse library 
To date we have transfected about 10,000 constructs of the library in single 
wells and we collected the relative results. We acquired pictures of plates after 
staining and of the specific wells with the most interesting results. Collection of 
the pictures, together with the collection of the data corresponding to the 
quantitation of the staining, was crucial to catalogue and record all the results of 
the screening (Fig. 19). 
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Quantitation of the staining was very important to select a pool of most relevant 
candidate genes: in fact, we established a threshold of the OD sample/OD 
positive control of differentiation value and on the basis of this value we were 
able to further consolidate our results. 
Up to now we have identified 650 candidate genes that correspond to 6.5% on 
the total number of the screened genes. 
 
13.2 - Analysis of candidate genes 
WE started with an in-silico analysis of our results using bioinformatic tools to 
obtain a Gene Ontology classification of the candidate genes (Carmona-Saez et 
al., 2007). We founded candidate genes involved in the signaling transduction, 
transcription process, transport within and between the cells and in the 
development (Fig. 20). 
It was interesting to find candidate genes belonging to the same pathway, such 
as apoptosis: this result further validate of our  screening system (Fig. 21). A 
remarkable result of the Gene Ontology analysis was to find a consistent 
fraction of genes with unknown function corresponding to the 30% of all the 
candidates arose from the screening. These genes belong to the riken 
collection. In particular we focused our attention on a short number of these 
genes and we named them ObI- that stands for Osteoblasts inducers-. These 
genes were were chosen on the basis of their putative function: in fact, 
bioinformatic analysis of the chosen genes predicted that they were 
transcription factors.  
We also considered  several genes identified during the screening whit a known 
function but an unknown role during the osteogenic differentiation process. 
Among these candidates we mainly focused on serine racemase gene.  
60 
 
 
 
Figure 18: Experimental approach validation 
Alizarin Red S staining after 21 days of: 1) untransfected W20-17 cells cultured in osteogenic 
medium; 2) untransfected W20-17 cells cultured in normal medium; 3) W20-17 cells transfected 
with shRNA Non Silencing and cultured in osteogenic medium; 4) W20-17 cells transfected with 
shRNA-SMAD5 and cultured in osteogenic medium; 5) W20-17 cells transfected with shRNA-
BMP1 and cultured in osteogenic medium (A). Calcium deposition was quantified using 
Guanidine HCl 4M and reading the adsorbance at 490 nm (B). 
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Figure 19: Representative image of a plate after Alizarin Red S staining 
This is a representative image of a plate as example of our screening results. Several wells 
don’t show red staining: genes silenced in these wells are putative candidates of our screening. 
 
 
 
Figure 20: Gene Ontology classification of candidates genes 
Results of Gene Ontology classification of the candidate genes arose from the first part of our 
screening. Biological processes represented by more than 3% of our candidates are shown in 
the graphic. 
 
 
14 - ObI-1 candidate gene 
 
14.1 - Interference with osteogenic differentiation 
Among the candidate genes with unknown function, interference with ObI-1 
gene with the corresponding shRNA construct of the library produced an almost 
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totally absence of Alizarin Red S staining in comparison to the positive control 
of differentiation. Furthermore, the effect seems to be specific of the action of 
the shRNA construct since the transfection with the shRNA-NS has produced 
the same effect of the positive control of differentiation (Fig. 22).  
 
 
Figure 21: Identification of a pathway involved in osteoblast differentiation (Apoptosis). 
Several gene of the apoptosis pathway were identified as candidate genes of our screening. 
Genes that are necessary for osteoblast development (i.e., absence of mineral deposit after 
silencing of these specific genes) are indicated with a star.  
 
 
After the result obtained from the screening, we repeated the interference 
experiment to confirm our data. We found two additional shRNA constructs 
interfering with ObI-1 gene so we also used them in confirmation experiments. 
Results obtained with all three constructs showed a significant reduction of 
osteogenic differentiation (Fig. 23A and 23B). These results confirmed the 
effects of the silencing of ObI-1 gene on osteogenic differentiation of W20-17. 
 
14.2 - Protein domains and phylogenetic analyses  
Prior to an experimental analysis of the role of ObI-1, we proceeded with an in-
silico analysis to try to better understand its structure and function. Analysis on 
Ensembl database showed two transcripts for ObI-1: a long form and a short 
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form (Fig 24A). Following analysis to find protein domains revealed the 
presence of a KRAB and several zinc-finger domains for the long form; short 
form contained only a KRAB domain (Fig. 24B). The phylogenetic analysis of 
ObI-1 gene was also performed on the Ensembl database. We found 
orthologue genes in many species: among these, were included the Human 
(Homo sapiens), Macaque (Macaca mulatta), Gorilla (Gorilla gorilla), Rat 
(Rattus norvegicus) and Cow (Bos Taurus) orthologues.  
 
 
 
Figure 22: ObI-1 results from the screening 
Alizarin Red S staining after culture in osteogenic medium for 21 days of: 1) W20-17 cells 
transfected with shRNA-ObI-1; 2) untransfected W20-17 cells; 3) W20-17 cells transfected with 
shRNA Non Silencing (A). Calcium deposition quantitation using Guanidine HCl 4M and 
adsorbance reading at 490 nm (B). 
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Figure 23: Confirmation of screening results on ObI-1  
Alizarin Red S staining after culture in osteogenic medium for 21 days of: 1) W20-17 cells 
transfected with shRNA-ObI-1#1 (shRNA construct used during the screening); 2-3) W20-17 
cells transfected with shRNA-ObI-1#2 and shRNA-ObI-1#3 (other two library constructs acting 
against ObI-1 gene); 4) W20-17 cells transfected with shRNA-Non Silencing; 5) Untransfected 
cells (A). Calcium deposition quantitation using Guanidine HCl 4M and adsorbance reading at 
490 nm (B). 
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ObI-1 (Short form)
ObI-1 (Long form)
 
Figure 24: Transcripts and proteins domains of ObI-1 gene  
Bionformatic analysis to search for transcripts of ObI-1 gene: two different transcripts are 
evident, a long  and a short form (A). Bioinformatic analysis to search for functional domains in 
the ObI-1 protein: long form present a KRAB domain and several Zinc finger domains, short 
form present only a KRAB domain (B). 
 
 
In total, 14 orthologue genes were present but only the Human and Rat genes 
correspond to demonstrated proteins while in other species their presence is 
only predicted.  
 
14.3 - Expression analyses  
 
14.3.1 - Expression analysis in tissues 
We first performed an in-silico analysis to evaluate the expression of ObI-1 in 
different tissues. Consulting UniGene database of NCBI (National Centry of 
Biotechnology Information) we looked for EST profile and we found the 
presence of our gene in different tissues with different levels (Fig 25). 
B 
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After bioinformatic analysis, we also performed Real-Time PCR experiments to 
directly evaluate the expression of ObI-1 in different mouse tissues (Fig. 26). 
 
14.3.2 - Expression analysis in W20-17 
Expression analysis of ObI-1 gene in W20-17 cell line was performed to 
evaluate the presence of its transcripts during osteogenic differentiation. We 
analyzed the presence of both Obi-1 transcripts, with Real-Time PCR 
experiments at different time-points (T0, corresponding to the undifferentiated 
cells, and T4, T14 and T21). The levels of the long form of ObI-1 increase at 
day 4 of differentiation and they remain high during all the process. The levels 
of the short form are very low, therefore they might not have a significant role 
(Fig. 27).  
 
 
Figure 25: In silico analysis of ObI-1 expression in tissues 
EST profile of ObI-1 transcript in mouse tissues 
(http://www.ncbi.nlm.nih.gov/UniGene/ESTProfileViewer.cgi?uglist=Mm.36612) 
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14.3.3 - Expression analysis in primary cells 
After analysis in W20-17 cell line, we also performed the expression analysis of 
ObI-1 gene in primary murine mesenchymal stem cells (mMSC). Also in this 
case we analyzed the presence of ObI-1 transcript by Real-Time PCR during 
osteogenic differentiation.  
We considered three different time points: T0, corresponding to undifferentiated 
cells, and T3 and T21. As well as in the osteogenic differentiation of W20-17 
cells, we detected an increase of ObI-1 transcript levels in osteogenic 
differentiation of mMSC: ObI-1 expression rose at day 4 and further increased 
at day 21 (Fig. 28). 
In addition to these data we also performed the expression analysis in 
adipogenic differentiation of MSC. We considered three different time points: 
the start point T0 and other two time points corresponding to T3 and T14. In this 
case we did not detect any increase of ObI-1 transcript levels during 
differentiation, but rather a decrease of the expression at day 14 (Fig. 29). 
 
14.4 - Sub cellular localization analysis 
In order to check for the sub-cellular  localization of the protein product of the 
ObI-1 gene we cloned the cDNA of ObI-1 in pcDNA3 (Invitrogen) with a Flag. 
We first found the expression of ObI-1 gene by Western Blot analysis 
comparing protein lysates obtained from W20-17 cells transfected with the 
pcDNA3 plasmid with or without the ObI-1 cDNA insert (Fig. 30). 
After this experiment we performed Immuno-fluorescence analysis to find the 
sub-cellular localization of ObI-1. Merge between the cells treated with DAPI 
and Anti-Flag antibody indicate the nuclear localization of Ob-1 gene (Fig. 31). 
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Figure 26: ObI-1 expression in tissues 
Expression profile of ObI-1 transcript in different tissues isolated form mouse. 
 
 
 
 
Figure 27: Expression analysis of ObI-1 during osteogenic differentiation of W20-17 
Expression profile of ObI-1 transcripts during osteogenic differentiation of W20-17 cells at day 0, 
4, 14 and 21. 
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15 - Serine racemase candidate gene 
 
15.1 - Interference with osteogenic differentiation 
Silencing of Serine racemase gene (Srr) produced a strong impairment of the 
osteogenic differentiation of W20-17 cells. Alizarin Red S staining of the cells 
transfected with the shRNA interfering with Srr showed a lack of differentiation 
into osteoblasts. Furthermore, cells transfected with the shRNA-NS show a 
phenotype similar to the one of the untransfected cells (Fig  32A and 32B). 
We also analyzed a second shRNA-Srr construct from our library that produced 
the same effect (Fig 32C and 32D). This results was very relevant in order to 
consider Srr gene as a good candidate. We then repeated the interference 
experiment to confirm the data. We were able to demonstrate and confirm the 
same inhibition effect on osteogenic differentiation for both the shRNA-Srr 
constructs. (Fig. 33A and 33B).   
 
15.2 - Expression analyses 
 
15.2.1 - Expression analysis in tissues  
We performed an in-silico analysis consulting UniGene database of NCBI 
(National Centry of Biotechnology Information).  We evaluated  EST profile and 
found the presence of Srr in different tissues, with the highest expression in 
bone (Fig 34). 
 
15.2.2 - Expression analysis in W2017 cell line 
We decided to evaluate the expression analysis of this candidate in our in-vitro 
differentiation system. At this purpose we performed a Real-Time PCR 
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experiment to evaluate for the presence and the possible variations of Srr 
transcript levels during the osteogenic differentiation of W20-17 cells. 
We considered four different time points during the process: T0, corresponding 
to the undifferentiated cells, T4, T14 and T21. Srr expression levels increase at 
day 4, remain high at day 14 and they further increase at day 21 (Fig. 35).  
 
 
15.3 - NMDA receptor expression in W20-17 cell line 
Subsequently to the analysis of the expression profile for Srr gene, we also 
investigated glutamate receptors presence in osteoblastic cell line W2017. Among 
the ionotropic glutamate receptors we found only the expression of the subunit R1 
of NMDA receptor in undifferentiated W20-17 cells, while the expression for AMPA 
and Kainate receptor genes seemed absent (Fig. 36A). In particular, Real-Time 
PCR experiments revealed that the NMDA-R1 subunit increases during the 
osteogenic differentiation process (Fig. 36B). 
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Figure 28: Expression analysis of ObI-1 during osteogenic differentiation of mMSC 
Expression profile of ObI-1 transcript during osteogenic differentiation of mMSC cells at day 0, 3 
and 21. 
 
 
 
Figure 29: Expression analysis of ObI-1 during adipogenic differentiation of mMSC 
Expression profile of ObI-1 transcript during adipogenic differentiation of mMSC cells at day 0, 3 
and 14. 
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Figure 30: Detection of pCDNA ObI-1-Flag by Western Blot analysis 
Protein lysate of cells transfected with pcDNA3 ObI-1 dual-Flag and not of cells transfected only 
with pcDNA3 was positive to anti-Flag antibody. GAPDH was used as control for each protein 
loading. 
 
 
 
 
Figure 31: Detection of ObI-1 sub-cellular localization by immunofluorescence analysis 
Expression of pcDNA3 ObI-1-confirm the nuclear localization of Obi-1. pcDNA3 expression was 
used as control. 
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Figure 32: Srr results from the screening 
Alizarin Red S staining after culture in osteogenic medium for 21 days of: 1) W20-17 cells 
transfected with shRNA-Srr #1; 2) W20-17 cells transfected with shRNA Non Silencing; 3) 
untransfected W20-17 cells (A). Calcium deposition quantitation using Guanidine HCl 4M and 
adsorbance reading at 490 nm (B). Alizarin Red S staining after culture in osteogenic medium 
for 21 days of: 4) W20-17 cells transfected with shRNA-Srr #2; 5) W20-17 cells transfected with 
shRNA Non Silencing; 6) untransfected W20-17 cells (C). Calcium deposition quantitation using 
Guanidine HCl 4M and adsorbance reading at 490 nm (D). 
 
 
 
 
 
Figure 33: Confirmation of screening results on Srr  
Alizarin Red S staining after culture in osteogenic medium for 21 days of: 1) W20-17 cells 
transfected with shRNA-Srr #1; 2) W20-17 cells transfected with shRNA-Srr #2; 3) W20-17 cells 
transfected with shRNA-Non Silencing; 4) Untransfected cells (A). Calcium deposition 
quantitation using Guanidine HCl 4M and adsorbance reading at 490 nm (B). 
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Figure 34: In silico analysis of ObI-1 expression in tissues 
EST profile of ObI-1 transcript in mouse tissues 
(http://www.ncbi.nlm.nih.gov/UniGene/ESTProfileViewer.cgi?uglist=Mm.131443). 
 
 
 
Figure 35: Expression analysis of Srr during osteogenic differentiation of W20-17 
Expression profile of Srr transcript during osteogenic differentiation of W20-17 cells at day 0, 4, 
14 and 21. 
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Figure 36: Expression of NMDA receptor in W20-17 
Expression analysis of NMDA, AMPA and Kainate receptors in undifferentiated W20-17 cells by 
RT-PCR. Expression in mouse brain was used as control (A). Expression analysis of NMDA-R1 
subunit during osteogenic differentiation by Real Time PCR of W20-17 at days 0, 4, 14 and 21 (B). 
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DISCUSSION 
 
 
16 -  shRNA-mediated screening for the identification of genes 
relevant for osteoblast differentiation 
 
16.1 - Set up 
The first step of this study was the set up of the components and the methods to 
perform the screening. We have decided to apply RNA-interference technique in a 
screening approach to investigate on new possible genes involved in osteogenic 
differentiation for two main reasons: the first consisted in a long-term interest of 
our laboratory in osteoblast differentiation and bone formation and the second was 
that we have access in our institute to a mouse library of short interfering RNA. 
An important boost to begin with our study came from the success of RNA 
approach in another line of research in our institute, with the same mouse shRNA 
library. In the above-mentioned research our colleagues found a gene essential for 
the maintenance of stemness of embryonic stem cells (ESc) evaluating the effects 
of the shRNAs on the neural differentiation of ESc (Parisi et al, 2009). 
We decided to evaluate osteogenic differentiation of murine Mesenchymal Stem 
Cells (mMSC); therefore we chose a specific cell line to use, a method to 
differentiate the cells into osteoblasts and a system to detect the osteogenic 
differentiation. Finally we had to adapt all these components to find the best 
conditions in order to carry out our experiments as high-throughput screening. 
We decided to use W20-17 among different types of MSC-derived cell lines since 
they are able to differentiate into osteoblasts. Furthermore, this cell line was 
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previously used by other authors to perform osteogenic differentiation experiments 
(Blum et al., 2001; Kempen et al., 2008). In order to differentiate W20-17 cells we 
used osteogenic medium (or D.A.G. medium): this medium consist in DMEM with 
10% serum supplemented with dexametasone, ascorbic acid 2P and β-
glicerophospate.  
Dexametasone is a glucocorticoids agonist capable to act on responsive 
promoters of transcription factors necessary for MSCs commitment for osteogenic 
lineage. Ascorbic acid 2P promotes the extracellular matrix formation and the 
maturation of all the types of collagens; furthermore, it induces the activity of 
plasma membrane-associated ALP in osteoprogenitors. β-glicerophospate 
promotes mineralization since phosphate gruoups are incorporated into 
idroxiapatite crystals of the matrix. 
Finally, we chose Alizarin Red S staining for osteogenic differentiation detection 
because it was largely described and used in literature and gave solid and 
reproducible results in our hands. 
 
16.2 - Experimental approach validation  
After the choice of all the components and methods, we had to establish and test 
the experimental conditions to adopt. This point was crucial to execute a reliable 
process to carry out the high-throughput screening of our assay with the library of 
shRNA constructs.   
Our experimental approach was the one described in the results: it implicates 
plating of the cells in 96-well microplates, transfection with the shRNA plasmids of 
the library, antibiotic treatment for 3 days in order to enrich for the cell population 
that incorporated the plasmids and finally osteogenic differentiation protocol. After 
the above-mentioned optimization, we had to test the functionality of the shRNA 
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plasmids for our purpose and above all the ability of our system to detect the 
osteogenic differentiation impairment by shRNA plasmids acting against candidate 
genes. We therefore performed the test that we described in the section 12.4 of 
the results in which we chose shRNA plasmids of the library interfering with genes 
whose role in osteogenic differentiation is largely described in literature.  
We obtained different grades of osteogenic differentiation impairment with these 
shRNA plasmids and this probably depended upon two principal reasons: the first 
reason was that not all the constructs of the library work with the same efficiency; 
the second reason consisted in the different grade of involvement in osteogenic 
differentiation process of the genes that we have silenced. 
The most important outcome from this experiment was the demonstration that 
using our experimental approach was possible to identify genes involved in 
osteogenic differentiation process and therefore we were able to proceed with the 
screening. 
 
16.3 - Implementation of the screening 
Performing of the screening was probably the most relevant commitment of this 
study. The libraries present in CEINGE are both human and mouse. We chose the 
mouse shRNA library because of the availability of murine mesenchymal stem 
cells-derived cell lines and the prospective to work with a mouse model for the 
best candidates. 
The mouse shRNA library is composed of 66,313 shRNA constructs 
corresponding to 699 plates; we were able to screen 1/7 of the library 
corresponding to 100 plates and about 10,000 constructs. A number of library 
plates contains genes whose function is unknown,  we have tried to reduce the 
presence of these plates, in order to screen a higher percentage of known murine 
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genes. So, even though we screened 1/7 of the total number of genes, we were 
able to screen about 1/3-1/4 of all the known genes in mouse. Nonetheless, we 
equally screened genes whose function is still unknown and, in fact, we have 
some of these genes among our candidates.  
Once performed part of the screening described in this study, we collected all the 
data and we chose a number of candidate genes establishing our choice on the 
basis of results from Alizarin Red S staining and its quantitation.  
As we mentioned in the section 13.1 of  the results, we found 650 candidate genes 
corresponding to 6.5% of the screened genes. This number of candidate genes 
may seems to be too high respect to number that one could imagine: in fact, it is 
difficult to state that approximately the 6% of the genes of an organism are 
implicated in osteoblast differentiation and bone formation. A possible explanation 
is that among the candidate genes are included genes whose function is essential 
for cell survival, independently from their role in osteoblast differentiation: 
therefore, the final effect is the impairment of osteoblast differentiation even 
though they are not implicated specifically in this process. 
After individuation of candidate genes we performed a Gene Ontology 
classification: our candidates were subdivided in different groups on the basis of 
their specific function or the process in which they are involved (Carmona-Saez et 
al., 2007). Most of our candidates are represented by genes with unknown 
function; this was a very interestingly results for two main reasons: they were 
about the 30% on the total number of the candidates and generally genes whose 
function is still unknown are a challenging subject to investigate. As regards the 
rest of the candidates with known functions, it was interesting to find a consistent 
number of genes belonging to the apoptosis pathway (Glynn Denis et al., 2003). 
This result validated our experimental approach: in fact, genes belonging to the 
same pathway, when induced in a process, should be almost all positive in a 
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screening. Furthermore, involvement of genes belonging to the apoptosis pathway 
in our study once more validated our screening system since some genes of 
apoptosis pathway, such as several caspases, had previously been demonstrated 
to be involved in osteoblast differentiation (Mogi and Togari, 2003). 
 
 
17 - ObI-1 candidate gene 
The effect of ObI-1 gene silencing in osteogenic differentiation was clear and 
therefore we focused our attention on this candidate. Furthermore, we found other 
constructs of the library that interfere with ObI-1 gene and therefore we could 
perform silencing confirmation experiments with three different constructs: this 
represent a specificity control for the RNA interference technique. In fact, in RNA-
interference experiments a molecule can cause off-target effects, independently by 
its activity on the putative mRNA target; if one obtain the same effects with other 
RNA molecules interfering with the same gene, it is possible to exclude off-target 
effects. This was our case and therefore we felt confident to go ahead with this 
candidate.  
After, we proceeded with an in-silico analysis, particularly required for genes with 
unknown function. Using Ensembl database we found two different transcripts for 
ObI-1 gene and, above all, we identified KRAB and zinc-finger functional domains 
in the corresponding protein. This results led us to hypothesize that this gene 
belongs to the family of the transcription factors with a KRAB domain (Urrutia, 
2003). To confirm this hypothesis we also performed immunofluorescence 
experiments to search for the sub-cellular localization of ObI-1. With these 
experiments we demonstrated the nuclear localization of ObI-1, reinforcing the 
idea that this gene may be a transcription factor.    
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Proceeding with the bioinformatic analysis, we demonstrated a possible 
conservation of this gene: in fact we found 14 orthologues in several species. It 
was interesting to find orthologues in Human with different levels of homology with 
the mouse gene. The better value of homology was about 46% for one of these 
orthologues: it was relevant to note that homology between the sequences occurs 
in the functional domains of the relative proteins.    
Expression analysis of ObI-1 in tissues was investigated with both in-silico 
analysis and Real-Time PCR experiments after RNA extraction from different 
tissues in mouse. In-silico analysis was performed by EST profile research on 
UniGene database of NCBI. An EST profiles can give an approximate gene 
expression pattern of a gene in different tissues since ESTs (Expressed Sequence 
Tag) are short fragments of transcripted DNA sequenced by cDNA obtained after 
retrotranscription of more long mRNA;  this RNA is isolated from different tissues. 
This analysis showed the presence of ObI-1 in few tissues with a little presence in 
bone marrow. Our analysis performed by Real-time PCR revealed a different 
distribution of ObI-1 gene in the tissues considered. We looked for the expression 
in bone, lung, heart, kidney, testis, liver, spleen and brain. We found a large 
amount of ObI-1 gene in lung, while no expression of ObI-1 was found in this 
organ by EST profile analysis. Also data about the other organs were different. 
Most important result consisted in the expression of ObI-1 in bone. Concerning the 
inconsistencies between the two analyses is important to say that the EST profile 
evaluation can be largely inconsistent: EST sequences are in fact not always 
correct since their sequencing is automated in only one direction and in a non-
overlapping manner. 
After analysis in tissues we also performed expression analysis in W20-17 cells to 
search for the presence of ObI-1 gene in our system. We analyzed the expression 
of ObI-1 transcripts during the osteogenic differentiation and we detected an 
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increase for the long form during the process respect to time 0 and very low levels 
of the short form during all the differentiation. Considering this analysis we 
hypothesized a possible role of ObI-1 gene in osteogenic differentiation of W20-17 
since its transcript increase since the day 4 of differentiation and remain high 
during all the process. Furthermore, after this experiments, we did not consider 
anymore the short form since its levels were very low.  
In order to complete the expression analysis in cells, we also performed 
experiment in primary mMSCs isolated from mouse in our laboratory (Esposito et 
al., 2009). Analysis in primary cells was very important because a cell line, such 
W20-17, do not exactly reproduce the physiological cellular environment. On the 
other hand, primary cells better reproduce the biochemical activities of cells in-
vivo: this was the reason why we decided to proceed with the analysis in these 
cells.  
Expression of ObI-1 gene during osteogenic differentiation of mMSCs was 
comparable to the data obtained in W20-17 cells. This further confirmed a role of 
our candidate in osteogenic differentiation. Furthermore, we also performed the 
expression analysis during MSCs adipogenic differentiation: in this case levels of 
the transcript did not increase during the process, but rather they appear even 
lower at the end of the differentiation compared to day 0. This latter result led us to 
consider a possible specific role of ObI-1 gene in the osteogenic differentiation of 
MSC considering the multipotency of these cells.  
 
 
18 - Serine Racemase candidate gene 
Regarding Srr racemase silencing effect on osteogenic differentiation, the most 
relevant result was the confirmation of the same effects with two indipendent 
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constructs of the library. This result was relevant also beca as blind experiment 
useful to demonstrate the specificity of the action of Srr gene on the osteogenic 
differentiation process. Following the first results from the screening, we 
repeated Srr silencing experiments and confirmed osteogenic differentiation 
impairment. The use of different shRNA constructs interfering with the same 
gene was once more an important result to demonstrate the specificity of RNA 
interference experiment. 
Srr expression in tissues, performed with an in-silico approach searching EST 
profile on UniGene database of NCBI,  revealed high expression of Srr in bone: 
this indicated a strong presence of this candidate in the system that we are 
studying. Expression analysis by Real-Time experiments in our cell system 
demonstrated the presence of the transcript in our cell system and its increase 
during the osteogenic differentiation process.  
Srr and D-serine have a great relevance in several neural disorders such as 
schizophrenia (Labrie et al., 2009) and Alzheimer disease (Hashimoto et al., 
2004; Inoue et al., 2008); they may also have a role in some bone disorders and 
this constitute an additional reason to study this gene. 
 
 
19 - Glutamate signaling in bone 
We analyze NMDA receptor expression in our system to verify the possible 
presence of a system analogous to glutamate signaling in the CNS as means of 
cellular communication. Demonstration of the expression of NMDA subunit R1 
in undifferentiated W20-17 cells and its increase during the osteogenic 
differentiation process may confirm a role of this receptor in our system. Other 
reasons that led us to hypothesize the presence of a glutamate signaling in our 
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system was the presence of candidates from our screening belonging to the 
glutamate signaling machinery: Glutamate receptor metabotropic 4 and 
Syntaxin 17. We just mentioned in the section 9.2 of the introduction the 
presence of several components of the glutamate signaling in bone and the 
prove of their functions and we were pleased to find some of these components 
in our screening. 
After demonstration of the presence of a possible glutamate-signaling network 
in bone, the question is why bone cells require fast excitatory neurotransmission 
as form of intracellular communication. One possible answer is represented by 
some evidences of memory formation in bone. It was described that responses 
to mechanical loading are affected by preceding episodes of loading: this  at 
least fulfill the conceptual requirement  for  long-term potentiation (LTP) -like 
directing the adaptive response of the skeleton to changing physical demand 
(Robling et al., 2002). It is in fact known that LTP mediated by NMDA receptor 
and its associated signaling apparatus is the molecular mechanism responsible 
for learning and memory formation. 
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Conclusions  
 
In this work we have described set up and implementation of a shRNA-mediated 
screening aimed at the identification of genes involved in osteoblast differentiation. 
Prior this study, this mouse shRNA library present in our institute was previously 
used by our colleagues to perform a screening to find genes involved in neural 
differentiation of ESCs. With our work we demonstrated versatility of this library 
and therefore the possibility to adapt this tool for different types of assay. In fact, 
the system that we have developed, allowed us to perform a screenings of mouse 
genes to identify those involved in osteoblast differentiation. The high-through put 
system can be adapted to pharmacological as well as other screenings to identify 
modulator of osteoblastic differentiation.  
A future perspective of this study consists in completing the characterization of the 
identified genes by morphological analysis in cells and in vivo data: in fact, their 
identification with the screening and the following analysis in the cellular system 
represents an interesting starting points to further investigate on their role in 
osteoblast differentiation and eventually to individuate new target for bone related 
pathologies in vivo.  
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